Late-stage CNS focus Reviva is a publicly traded, late-stage clinical development company actively advancing a lead multimodal neuromodulator (RP5063) through Phase 3 for schizophrenia and potential expansion into bipolar disorder, MDD, ADP, PDP, ADD/ADHD and autism. This presents high-potential collaboration and licensing opportunities with pharma companies seeking late-stage CNS assets and candidates for acquisition or partnership.

Global Phase 3 readiness Following a successful End of Phase 2 meeting with the FDA, Reviva plans to initiate global Phase 3 trials for RP5063 in schizophrenia, signaling near-term acceleration and a timeline that can align with partner-provided funding, manufacturing capacity, and global commercialization support.

Diverse disease portfolio Beyond RP5063, Reviva targets CNS, inflammatory and cardiometabolic diseases with internally discovered therapies using chemical genomic approaches, indicating multiple avenues for co-development, out-licensing, or strategic alliances across adjacent therapeutic areas.

Investor-backed growth With funding of about 167 million and revenue in the 10 to 25 million range, Reviva combines a solid financial footing with ongoing capital markets activity, creating opportunities for strategic investors and partners to engage in joint development funding, milestone-based deals, or equity financing arrangements.

Engagement and visibility Active participation in neuroscience and healthcare events, investor conferences, and ongoing communications suggest strong visibility with thought leaders and potential partners. This presents opportunities for targeted outreach, co-promotional discussions, and early engagement with decision-makers following conference presentations.